A Phase 2 interventional study of BMS-986177 and Placebo in Acute Ischemic Stroke and Transient Ischemic Attack (TIA), sponsored by Bristol-Myers Squibb. Completed at 424 sites in 29 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2023-06-12.
Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 480 studies in Ischemic Stroke with a site in United States — 122 open to participants now, 146 under way, 13 of them phase 3. Ischemic Stroke · United States.
Among the 480 studies in Ischemic Stroke with a site in United States, this one is the 12th largest by enrollment of the 364 interventional ones that give a count, is one of 25 that started in 2019, is one of 71 in phase 2, and was the 229th registered.
2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.
Browse Ischemic Stroke studies →122 of the 480 studies in Ischemic Stroke with a site in United States are open now. Recruiting first, the newest first:
Casa Colina Hospital and Centers for Healthcare · Sites in United States
Ages 18+
Magnetic Tides · Sites in United States
Ages 18–80
Vanderbilt University Medical Center · Sites in United States
Ages 18+
Abrexa Pharmaceuticals, Inc. · Sites in United States
Ages 18–90
Medtronic Neurovascular Clinical Affairs · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
480 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 56 · Phase 2 103 · Phase 3 46 · Phase 4 11
First in 1993; this study’s year is marked. 25 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,366 is above the median of 120 across 1,781 interventional studies indexed under Ischemic Stroke.
Median enrollment 66 across the 364 interventional studies, 300 across the 111 observational. Of the 281 that completed or were terminated, 128 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
154 of 480 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Bristol-Myers Squibb has 2 studies filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
48 of the studies in Ischemic Stroke with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05065216Phase 3DiaMedica Therapeutics IncTreatment of Acute Ischemic Stroke (ReMEDy2 Trial) | 2026-12 |
| NCT03223220Phase 3Lower Merion Neurology Research FoundationQuelling of Excitotoxicity in Acute Stroke With Ketamine | 2026-12-31 |
| NCT05691244Phase 3Pharmazz, Inc.Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke | 2027-09 |
| NCT07649135University of MinnesotaFeasibility of a Remotely Delivered Step Count Intervention in Chronic Stroke | 2026-11-30 |
| NCT05085210Beth Israel Deaconess Medical CenterImproving Visual Field Deficits With Noninvasive Brain Stimulation | 2026-12 |
Add all 48 to your calendar (.ics) → With an account.
Among the 480 studies in Ischemic Stroke with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical study is to determine whether the addition of an oral Factor XIa Inhibitor to Aspirin and Clopidogrel is more effective than standard therapy in secondary stroke prevention.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria could apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Specified Dose on Specified Days
Other: Placebo · Drug: Clopidogrel · Drug: Aspirin
Specified Dose on Specified Days
Drug: BMS-986177 · Drug: Clopidogrel · Drug: Aspirin
Specified Dose on Specified Days
Drug: BMS-986177 · Drug: Clopidogrel · Drug: Aspirin
Specified Dose on Specified Days
Drug: BMS-986177 · Drug: Clopidogrel · Drug: Aspirin
Specified Dose on Specified Days
Drug: BMS-986177 · Drug: Clopidogrel · Drug: Aspirin
Specified Dose on Specified Days
Drug: BMS-986177 · Drug: Clopidogrel · Drug: Aspirin
Specified Dose on Specified Days
Drug: BMS-986177 · Drug: Clopidogrel · Drug: Aspirin
Specified Dose on Specified Days
Drug: BMS-986177 · Drug: Clopidogrel · Drug: Aspirin
Oral administration
Oral Administration
Oral administration
Oral administration
Percent of Participants With Model Based Assessment of Composite of New Ischemic Stroke During Treatment and New Covert Brain Infarction (FLAIR + DWI) Detected by MRI by Day 90
Model based assessment estimate for composite event is a customized statistical analysis called MCP-MOD (Multiple Comparison Procedures, MODel) estimation, which is used to check for dose-response relationship. 95% confidence interval (CI) for composite event based on bootstrap (10000 samples).
Time frame: From randomization to up to 90 days after randomization
Percent of Participants With Major Bleeding According to BARC Type 3 and 5
Percent of participants with major bleeding based on the Bleeding Academic Research Consortium (BARC) Types 3 and 5 definitions. BARC bleeding types: 3a = Overt bleeding plus hemoglobin drop of 3 to \< 5 g/dL transfusion with overt bleeding 3b = Overt bleeding plus hemoglobin drop ≥5 g/dL; cardiac tamponade; bleeding requiring surgical intervention for control; bleeding requiring IV vasoactive agents 3c = Intracranial hemorrhage, 5a = Probable fatal bleeding 5b = Definite fatal bleeding
Time frame: From first dose to up to 107 days after first dose
Number of Participants With Bleeding Based on BARC Types 1-5
Number of participants with bleeding based on Bleeding Academic Research Consortium (BARC) Type 1 to 5. BARC bleeding types: 0=No bleeding. 1=Not actionable bleeding. 2=Overt, actionable sign of hemorrhage requiring nonsurgical, medical intervention by a health-care professional, leading to hospitalization or increased level of care, or prompting evaluation. 3a=Overt bleeding plus hemoglobin drop of 3 to \< 5 g/dL. 3b=Overt bleeding plus hemoglobin drop ≥5 g/dL; cardiac tamponade; bleeding requiring surgical intervention; bleeding requiring IV vasoactive agents. 3c=Intracranial hemorrhage; intraocular bleed compromising vision. 4=CABG-related bleeding, perioperative intracranial bleeding within 48 hours, reoperation after closure of sternotomy to control bleeding, transfusion of ≥5 U whole blood or packed red blood cells within a 48-hour period, chest tube output more than or equal to 2L within a 24-hour period. 5a=Probable fatal bleeding. 5b=Definite fatal bleeding.
Time frame: From first dose to up to 107 days after first dose
Number of Participants With Bleeding Based on ISTH-Defined Criteria
Number of participants with bleeding based on International Society on Thrombosis and Hemostasis (ISTH). ISTH Bleeding Types: 1) Fatal bleeding and/or 2) Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome and/or 3) Bleeding causing a fall in hemoglobin level of ≥2 g/dL, or leading to transfusion of ≥2 units of whole blood or red cells.
Time frame: From first dose to up to 107 days after first dose
Number of Participants With Bleeding Based on PLATO-Defined Criteria
Number of participants with bleeding based on Platelet Inhibition and Patient Outcomes (PLATO) defined criteria. PLATO bleeding definitions: 1. Major Life-threatening: Fatal, Intracranial, Intrapericardial with cardiac tamponade, Resulting in hypovolemic shock or severe hypotension that requires pressors or surgery, Clinically overt or apparent bleeding associated with decrease in hemoglobin \>5 g/dL, Requiring transfusion of ≥4 U whole blood or packed red blood cells (PRBCs) 2. Other Major: Significantly disabling (eg, intraocular with permanent vision loss), Associated drop in hemoglobin of 3 to 5 g/dL, Requiring transfusion of 2 to 3 U whole blood or PRBCs 3. Any Major: Any one of the above criteria 4. Minor: Bleeding that does not meet criteria for PLATO Major bleeding, and requiring medical intervention
Time frame: From first dose to up to 107 days after first dose
Percent of Participants With Descriptive Assessment of Composite of New Ischemic Stroke During Treatment and New Covert Brain Infarction (FLAIR + DWI) Detected by MRI by Day 90
Descriptive Assessment of Composite of New Ischemic Stroke During Treatment and New Covert Brain Infarction (FLAIR + DWI) Detected by MRI by Day 90.
Time frame: From randomization to up to 90 days after randomization
Composite of Percent of Participants With New Ischemic Stroke, MI and All Cause Death
Composite of percent of participants of new ischemic stroke, (Myocardial Infarction) MI and all cause death.
Time frame: From randomization to up to 90 days after randomization
National Institutes of Health Stroke Scale (NIHSS)
The NIHSS is an 11-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. The score for each ability is a number between 0 and 4, 0 being normal functioning and 4 being completely impaired. The patient's NIHSS score is calculated by adding the number for each element of the scale; 42 is the highest score possible. In the NIHSS, the higher the score, the more impaired a stroke participant is.
Time frame: At baseline, on Days 21 and 90, and at the time of a new stroke event
Modified Rankin Scale (mRS)
The Modified Rankin Score (mRS) is a 6-point disability scale with possible scores ranging from 0 to 6. 0 = No symptoms at all 1. = No significant disability despite symptoms; able to carry out all usual duties and activities 2. = Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance 3. = Moderate disability; requiring some help, but able to walk without assistance 4. = Moderately severe disability; unable to walk and attend to bodily needs without assistance 5. = Severe disability; bedridden, incontinent and requiring constant nursing care and attention 6. = Dead
Time frame: At baseline, on Days 21 and 90, and at the time of a new stroke event
Montreal Cognitive Assessment (MoCA)
The Montreal Cognitive Assessment (MoCA) is a survey with a summed score. MoCA score ranges between a lowest score of 0 to a highest score of 30. A score of: * ≥26 points: indicates normal cognitive function * 18-25 points: Mild cognitive impairment * 10-17 points: Moderate cognitive impairment * fewer than 10 points: Severe cognitive impairment
Time frame: At baseline, on Days 21 and 90, and at the time of a new stroke event
Digit Symbol Substitution Test (DSST)
The Descriptive Summary of the Digit Symbol Substitution Test (DSST) is a scale item, with a lowest score of 0 and highest total score of 135. Higher score indicates better cognitive functioning.
Time frame: At baseline, on Days 21 and 90, and at the time of a new stroke event
Number of Participants With Adverse Events (AEs)
AE: include all non-serious adverse events with onset on or after first dose date and within 2 days after the last dose of study treatment.
Time frame: From first dose to 2 days after last dose of study therapy (up to approximately 107 days)
Number of Participants With Clinically Significant Vital Sign Abnormalities
Number of participants with clinically significant vital sign abnormalities. Vital signs included heart rate and diastolic and systolic blood pressure.
Time frame: From first dose to up to 90 days after first dose
Number of Participants With Clinically Significant Physical Examination Abnormalities
Number of participants with clinically significant physical examination abnormalities.
Time frame: From first dose to up to 90 days after first dose
Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities
Number of participants with clinically significant ECG abnormalities.
Time frame: From first dose to up to 90 days after first dose
Number of Participants With Clinically Significant Laboratory Abnormalities - Liver
The number of treated participants who experienced a laboratory abnormality of the liver during the course of the study. Aspartate aminotransferase (AST) Alanine aminotransferase (ALT) Upper Limit of Normal (ULN) Results reported in International System of Units (SI)
Time frame: From first dose to up to approximately 38 months
Percent Change From Baseline in aPTT Activity
Percent change from baseline in activated partial thromboplastin time (aPTT) activity via exposure response.
Time frame: Baseline and day 90
Percent Change From Baseline in Factor XI Clotting Activity
Percent change from baseline in factor XI clotting activity via exposure response.
Time frame: Baseline and day 90
Pharmacokinetic Parameter - Estimated Clearance (CL)
Pharmacokinetic Parameter - Estimated Clearance (CL). CL is derived from plasma concentration versus time data. PK parameters were generated using a Population Pharmacokinetics (PPK) model. Summary statistics for these individual predicted PK parameters and exposures were stratified by dose. The PPK model analysis was based on combined PK data collected on days 1, 21, and 90.
Time frame: From first dose to up to 90 days after first dose
Pharmacokinetic Parameter - Volume of the Central Compartment (VC)
Pharmacokinetic Parameter - Volume of the Central Compartment (VC). VC is derived from plasma concentration versus time data. PK parameters were generated using a Population Pharmacokinetics (PPK) model. Summary statistics for these individual predicted PK parameters and exposures were stratified by dose. The PPK model analysis was based on combined PK data collected on days 1, 21, and 90.
Time frame: From first dose to up to 90 days after first dose
Volume of Incident Infarcts (New DWI+ or DWI- Lesions) by Participant on Day 90 MRI
Total volume of diffusion-weighted imaging (DWI) magnetic resonance imaging (MRI) infarcts on the DWI Sequence on day 90 MRI.
Time frame: At day 90
Number of Incident Infarcts (New DWI+ or DWI- Lesions) by Participant on Day 90 MRI
Number of diffusion-weighted imaging (DWI) magnetic resonance imaging (MRI) infarcts on the DWI Sequence on day 90 MRI.
Time frame: At day 90
Percent of Participants With Ischemic Stroke Events
Secondary analysis of symptomatic ischemic stroke events. Clinical events are included up to day 90. Wald 95% CI within group. Undetermined stroke is included.
Time frame: From randomization to up to 90 days after randomization
| Milestone | Placebo | Milvexian 25 mg QD | Milvexian 25 mg BID | Milvexian 50 mg BID | Milvexian 100 mg BID | Milvexian 200 mg BID | Milvexian 50 mg QD | Milvexian 100 mg QD |
|---|---|---|---|---|---|---|---|---|
| Started | 691 | 328 | 318 | 328 | 310 | 351 | 22 | 18 |
| Completed | 682 | 324 | 313 | 325 | 306 | 345 | 22 | 17 |
| Not completed | 9 | 4 | 5 | 3 | 4 | 6 | 0 | 1 |
| Withdrew: Other reasons | 2 | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Participant no longer meets study criteria | 5 | 3 | 4 | 0 | 2 | 3 | 0 | 1 |
| Withdrew: Participant request to discontinue study treatment | 1 | 0 | 0 | 0 | 1 | 2 | 0 | 0 |
| Withdrew: Participant withdrew consent | 1 | 0 | 1 | 2 | 1 | 1 | 0 | 0 |
| Milestone | Placebo | Milvexian 25 mg QD | Milvexian 25 mg BID | Milvexian 50 mg BID | Milvexian 100 mg BID | Milvexian 200 mg BID | Milvexian 50 mg QD | Milvexian 100 mg QD |
|---|---|---|---|---|---|---|---|---|
| Started | 682 | 325 | 313 | 325 | 306 | 344 | 22 | 17 |
| Completed | 529 | 260 | 242 | 251 | 230 | 240 | 15 | 14 |
| Not completed | 153 | 65 | 71 | 74 | 76 | 104 | 7 | 3 |
| Withdrew: Adverse event | 82 | 44 | 47 | 46 | 50 | 77 | 5 | 2 |
| Withdrew: Participant request to discontinue treatment | 34 | 6 | 10 | 10 | 14 | 15 | 0 | 1 |
| Withdrew: Participant withdrew consent | 11 | 4 | 5 | 5 | 4 | 4 | 0 | 0 |
| Withdrew: Death | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Poor/non compliance | 2 | 2 | 1 | 1 | 1 | 1 | 0 | 0 |
| Withdrew: Participant no longer meets study criteria | 9 | 1 | 5 | 4 | 4 | 4 | 2 | 0 |
| Withdrew: Other reasons | 13 | 8 | 3 | 7 | 3 | 3 | 0 | 0 |
Model based assessment estimate for composite event is a customized statistical analysis called MCP-MOD (Multiple Comparison Procedures, MODel) estimation, which is used to check for dose-response relationship. 95% confidence interval (CI) for composite event based on bootstrap (10000 samples).
| Percentage of participants | Placebo | Milvexian 25 mg QD | Milvexian 25 mg BID | Milvexian 50 mg BID | Milvexian 100 mg BID | Milvexian 200 mg BID |
|---|---|---|---|---|---|---|
| Percent of Participants With Model Based Assessment of Composite of New Ischemic Stroke During Treatment and New Covert Brain Infarction (FLAIR + DWI) Detected by MRI by Day 90 | 16.8 (14.2 to 19.4) | 16.7 (14.4 to 19.0) | 16.6 (14.5 to 18.7) | 15.6 (13.6 to 17.9) | 15.4 (13.0 to 18.0) | 15.3 (12.3 to 20.4) |
Percent of participants with major bleeding based on the Bleeding Academic Research Consortium (BARC) Types 3 and 5 definitions. BARC bleeding types: 3a = Overt bleeding plus hemoglobin drop of 3 to \< 5 g/dL transfusion with overt bleeding 3b = Overt bleeding plus hemoglobin drop ≥5 g/dL; cardiac tamponade; bleeding requiring surgical intervention for control; bleeding requiring IV vasoactive agents 3c = Intracranial hemorrhage, 5a = Probable fatal bleeding 5b = Definite fatal bleeding
| Percentage of participants | Placebo | Milvexian 25 mg QD | Milvexian 25 mg BID | Milvexian 50 mg BID | Milvexian 100 mg BID | Milvexian 200 mg BID | Milvexian 50 mg QD | Milvexian 100 mg QD |
|---|---|---|---|---|---|---|---|---|
| Percent of Participants With Major Bleeding According to BARC Type 3 and 5 | 0.6 (0.2 to 1.5) | 0.6 (0.1 to 2.2) | 0.6 (0.1 to 2.3) | 1.5 (0.5 to 3.6) | 1.6 (0.5 to 3.8) | 1.5 (0.5 to 3.4) | 0 (0 to 15.4) | 0 (0 to 19.5) |
Number of participants with bleeding based on Bleeding Academic Research Consortium (BARC) Type 1 to 5. BARC bleeding types: 0=No bleeding. 1=Not actionable bleeding. 2=Overt, actionable sign of hemorrhage requiring nonsurgical, medical intervention by a health-care professional, leading to hospitalization or increased level of care, or prompting evaluation. 3a=Overt bleeding plus hemoglobin drop of 3 to \< 5 g/dL. 3b=Overt bleeding plus hemoglobin drop ≥5 g/dL; cardiac tamponade; bleeding requiring surgical intervention; bleeding requiring IV vasoactive agents. 3c=Intracranial hemorrhage; intraocular bleed compromising vision. 4=CABG-related bleeding, perioperative intracranial bleeding within 48 hours, reoperation after closure of sternotomy to control bleeding, transfusion of ≥5 U whole blood or packed red blood cells within a 48-hour period, chest tube output more than or equal to 2L within a 24-hour period. 5a=Probable fatal bleeding. 5b=Definite fatal bleeding.
| Participants | Placebo | Milvexian 25 mg QD | Milvexian 25 mg BID | Milvexian 50 mg BID | Milvexian 100 mg BID | Milvexian 200 mg BID | Milvexian 50 mg QD | Milvexian 100 mg QD |
|---|---|---|---|---|---|---|---|---|
| Type 1 | 41 | 26 | 16 | 28 | 25 | 22 | 5 | 2 |
| Type 2 | 9 | 7 | 9 | 7 | 10 | 8 | 1 | 1 |
| Type 3A | 2 | 1 | 1 | 1 | 2 | 3 | 0 | 0 |
| Type 3B | 0 | 1 | 1 | 1 | 3 | 1 | 0 | 0 |
| Type 3C | 2 | 0 | 0 | 3 | 0 | 1 | 0 | 0 |
| Type 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Type 5A | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Type 5B | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Number of participants with bleeding based on International Society on Thrombosis and Hemostasis (ISTH). ISTH Bleeding Types: 1) Fatal bleeding and/or 2) Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome and/or 3) Bleeding causing a fall in hemoglobin level of ≥2 g/dL, or leading to transfusion of ≥2 units of whole blood or red cells.
| Participants | Placebo | Milvexian 25 mg QD | Milvexian 25 mg BID | Milvexian 50 mg BID | Milvexian 100 mg BID | Milvexian 200 mg BID | Milvexian 50 mg QD | Milvexian 100 mg QD |
|---|---|---|---|---|---|---|---|---|
| Major | 4 | 2 | 2 | 5 | 6 | 5 | 0 | 0 |
| Clinically Relevant Non-Major (CRNM) | 7 | 8 | 9 | 7 | 8 | 8 | 1 | 1 |
| Major or CRNM | 11 | 10 | 11 | 12 | 14 | 13 | 1 | 1 |
| Minor Bleed | 43 | 25 | 16 | 28 | 26 | 22 | 5 | 2 |
Number of participants with bleeding based on Platelet Inhibition and Patient Outcomes (PLATO) defined criteria. PLATO bleeding definitions: 1. Major Life-threatening: Fatal, Intracranial, Intrapericardial with cardiac tamponade, Resulting in hypovolemic shock or severe hypotension that requires pressors or surgery, Clinically overt or apparent bleeding associated with decrease in hemoglobin \>5 g/dL, Requiring transfusion of ≥4 U whole blood or packed red blood cells (PRBCs) 2. Other Major: Significantly disabling (eg, intraocular with permanent vision loss), Associated drop in hemoglobin of 3 to 5 g/dL, Requiring transfusion of 2 to 3 U whole blood or PRBCs 3. Any Major: Any one of the above criteria 4. Minor: Bleeding that does not meet criteria for PLATO Major bleeding, and requiring medical intervention
| Participants | Placebo | Milvexian 25 mg QD | Milvexian 25 mg BID | Milvexian 50 mg BID | Milvexian 100 mg BID | Milvexian 200 mg BID | Milvexian 50 mg QD | Milvexian 100 mg QD |
|---|---|---|---|---|---|---|---|---|
| MAJOR LIFE-THREATENING | 2 | 1 | 1 | 4 | 3 | 2 | 0 | 0 |
| OTHER MAJOR BLEEDING | 2 | 1 | 1 | 1 | 2 | 3 | 0 | 0 |
| ANY MAJOR | 4 | 2 | 2 | 5 | 5 | 5 | 0 | 0 |
| MINOR | 7 | 6 | 7 | 7 | 9 | 9 | 0 | 1 |
| MINIMAL | 43 | 27 | 18 | 28 | 26 | 21 | 6 | 2 |
Descriptive Assessment of Composite of New Ischemic Stroke During Treatment and New Covert Brain Infarction (FLAIR + DWI) Detected by MRI by Day 90.
| Percentage of participants | Placebo | Milvexian 25 mg QD | Milvexian 25 mg BID | Milvexian 50 mg BID | Milvexian 100 mg BID | Milvexian 200 mg BID | Milvexian 50 mg QD | Milvexian 100 mg QD |
|---|---|---|---|---|---|---|---|---|
| Percent of Participants With Descriptive Assessment of Composite of New Ischemic Stroke During Treatment and New Covert Brain Infarction (FLAIR + DWI) Detected by MRI by Day 90 | 16.6 | 16.2 | 18.5 | 14.1 | 14.8 | 16.4 | 19.0 | 18.8 |
Composite of percent of participants of new ischemic stroke, (Myocardial Infarction) MI and all cause death.
| Percentage of participants | Placebo | Milvexian 25 mg QD | Milvexian 25 mg BID | Milvexian 50 mg BID | Milvexian 100 mg BID | Milvexian 200 mg BID | Milvexian 50 mg QD | Milvexian 100 mg QD |
|---|---|---|---|---|---|---|---|---|
| Composite of Percent of Participants With New Ischemic Stroke, MI and All Cause Death | 6.1 (4.3 to 7.9) | 5.2 (2.8 to 7.6) | 4.7 (2.4 to 7.0) | 4.9 (2.5 to 7.2) | 5.2 (2.7 to 7.6) | 9.4 (6.3 to 12.5) | 18.2 (2.1 to 34.3) | 5.6 (0 to 16.1) |
The NIHSS is an 11-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. The score for each ability is a number between 0 and 4, 0 being normal functioning and 4 being completely impaired. The patient's NIHSS score is calculated by adding the number for each element of the scale; 42 is the highest score possible. In the NIHSS, the higher the score, the more impaired a stroke participant is.
| Score on a scale | Placebo | Milvexian 25 mg QD | Milvexian 25 mg BID | Milvexian 50 mg BID | Milvexian 100 mg BID | Milvexian 200 mg BID | Milvexian 50 mg QD | Milvexian 100 mg QD |
|---|---|---|---|---|---|---|---|---|
| Baseline | 1.6 ± 1.87 | 1.7 ± 1.68 | 1.6 ± 1.73 | 1.6 ± 1.79 | 1.8 ± 1.81 | 1.6 ± 1.79 | 1.1 ± 1.44 | 2.0 ± 1.70 |
| Day 21 | 0.9 ± 2.11 | 0.8 ± 1.35 | 0.8 ± 1.43 | 0.8 ± 1.58 | 0.8 ± 1.48 | 0.9 ± 1.88 | 0.8 ± 1.90 | 0.9 ± 1.39 |
| Day 90 | 0.5 ± 1.40 | 0.6 ± 1.06 | 0.6 ± 1.51 | 0.6 ± 1.14 | 0.6 ± 1.32 | 0.6 ± 1.29 | 0.3 ± 0.72 | 0.6 ± 1.45 |
| First recurrent stroke | 6.2 ± 5.01 | 4.6 ± 6.79 | 5.4 ± 3.17 | 4.6 ± 4.30 | 7.1 ± 4.68 | 4.4 ± 4.60 | 5.3 ± 3.06 | 1.0 ± NA |
The Modified Rankin Score (mRS) is a 6-point disability scale with possible scores ranging from 0 to 6. 0 = No symptoms at all 1. = No significant disability despite symptoms; able to carry out all usual duties and activities 2. = Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance 3. = Moderate disability; requiring some help, but able to walk without assistance 4. = Moderately severe disability; unable to walk and attend to bodily needs without assistance 5. = Severe disability; bedridden, incontinent and requiring constant nursing care and attention 6. = Dead
| Score on a scale | Placebo | Milvexian 25 mg QD | Milvexian 25 mg BID | Milvexian 50 mg BID | Milvexian 100 mg BID | Milvexian 200 mg BID | Milvexian 50 mg QD | Milvexian 100 mg QD |
|---|---|---|---|---|---|---|---|---|
| Baseline | 0.5 ± 0.87 | 0.6 ± 0.95 | 0.6 ± 0.96 | 0.5 ± 0.86 | 0.5 ± 0.89 | 0.6 ± 0.95 | 0.2 ± 0.53 | 0.7 ± 0.99 |
| Day 21 | 1.0 ± 1.18 | 1.0 ± 1.13 | 0.9 ± 1.15 | 0.9 ± 1.15 | 1.0 ± 1.17 | 0.9 ± 1.19 | 0.9 ± 1.27 | 1.3 ± 1.14 |
| Day 90 | 0.7 ± 1.04 | 0.8 ± 1.04 | 0.8 ± 1.07 | 0.7 ± 1.01 | 0.7 ± 1.01 | 0.8 ± 1.05 | 0.6 ± 1.05 | 1.0 ± 1.11 |
| First recurrent stroke | 3.0 ± 1.60 | 2.7 ± 1.03 | 2.6 ± 1.35 | 2.3 ± 1.62 | 2.9 ± 1.64 | 1.8 ± 1.72 | 2.0 ± 0.00 | 1.0 ± NA |
The Montreal Cognitive Assessment (MoCA) is a survey with a summed score. MoCA score ranges between a lowest score of 0 to a highest score of 30. A score of: * ≥26 points: indicates normal cognitive function * 18-25 points: Mild cognitive impairment * 10-17 points: Moderate cognitive impairment * fewer than 10 points: Severe cognitive impairment
| Score on a scale | Placebo | Milvexian 25 mg QD | Milvexian 25 mg BID | Milvexian 50 mg BID | Milvexian 100 mg BID | Milvexian 200 mg BID | Milvexian 50 mg QD | Milvexian 100 mg QD |
|---|---|---|---|---|---|---|---|---|
| Baseline | 22.3 ± 5.06 | 21.6 ± 5.59 | 22.0 ± 5.18 | 22.5 ± 4.82 | 22.4 ± 5.04 | 22.1 ± 5.31 | 24.4 ± 3.84 | 22.0 ± 4.59 |
| Day 21 | 24.0 ± 4.77 | 23.9 ± 5.01 | 24.0 ± 4.70 | 24.3 ± 4.57 | 23.6 ± 4.48 | 24.0 ± 4.96 | 26.4 ± 2.61 | 24.1 ± 4.70 |
| Day 90 | 24.6 ± 4.54 | 24.0 ± 4.69 | 24.2 ± 4.80 | 24.4 ± 4.48 | 24.5 ± 4.36 | 24.2 ± 5.05 | 25.0 ± 4.72 | 26.4 ± 1.69 |
| First recurrent stroke | 23.2 ± 6.63 | 17.3 ± 6.11 | 25.3 ± 2.31 | 19.0 ± 8.49 | 3.0 ± NA | 23.1 ± 7.08 | 11.0 ± NA | 22.0 ± NA |
The Descriptive Summary of the Digit Symbol Substitution Test (DSST) is a scale item, with a lowest score of 0 and highest total score of 135. Higher score indicates better cognitive functioning.
| Score on a scale | Placebo | Milvexian 25 mg QD | Milvexian 25 mg BID | Milvexian 50 mg BID | Milvexian 100 mg BID | Milvexian 200 mg BID | Milvexian 50 mg QD | Milvexian 100 mg QD |
|---|---|---|---|---|---|---|---|---|
| Baseline | 34.9 ± 22.36 | 31.2 ± 18.87 | 32.9 ± 22.89 | 37.2 ± 25.67 | 33.7 ± 21.89 | 31.7 ± 19.15 | 47.1 ± 29.34 | 29.2 ± 18.16 |
| Day 21 | 41.2 ± 22.14 | 38.9 ± 19.27 | 40.2 ± 21.60 | 45.1 ± 25.77 | 41.2 ± 22.87 | 39.1 ± 21.35 | 54.6 ± 32.73 | 37.1 ± 20.13 |
| Day 90 | 42.8 ± 21.18 | 41.7 ± 21.66 | 41.3 ± 20.29 | 45.2 ± 21.86 | 45.5 ± 23.44 | 41.4 ± 21.97 | 47.5 ± 27.48 | 40.7 ± 17.46 |
| First recurrent stroke | 36.3 ± 13.56 | 28.0 ± 20.95 | 42.0 ± 4.36 | 40.5 ± 2.12 | 23.0 ± NA | 27.5 ± 16.96 | 9.0 ± NA | 47.0 ± NA |
AE: include all non-serious adverse events with onset on or after first dose date and within 2 days after the last dose of study treatment.
| Participants | Placebo | Milvexian 25 mg QD | Milvexian 25 mg BID | Milvexian 50 mg BID | Milvexian 100 mg BID | Milvexian 200 mg BID | Milvexian 50 mg QD | Milvexian 100 mg QD |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With Adverse Events (AEs) | 399 | 190 | 186 | 192 | 193 | 211 | 11 | 13 |
Number of participants with clinically significant vital sign abnormalities. Vital signs included heart rate and diastolic and systolic blood pressure.
| Participants | Placebo | Milvexian 25 mg QD | Milvexian 25 mg BID | Milvexian 50 mg BID | Milvexian 100 mg BID | Milvexian 200 mg BID | Milvexian 50 mg QD | Milvexian 100 mg QD |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With Clinically Significant Vital Sign Abnormalities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Number of participants with clinically significant physical examination abnormalities.
| Participants | Placebo | Milvexian 25 mg QD | Milvexian 25 mg BID | Milvexian 50 mg BID | Milvexian 100 mg BID | Milvexian 200 mg BID | Milvexian 50 mg QD | Milvexian 100 mg QD |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With Clinically Significant Physical Examination Abnormalities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Number of participants with clinically significant ECG abnormalities.
| Participants | Placebo | Milvexian 25 mg QD | Milvexian 25 mg BID | Milvexian 50 mg BID | Milvexian 100 mg BID | Milvexian 200 mg BID | Milvexian 50 mg QD | Milvexian 100 mg QD |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
The number of treated participants who experienced a laboratory abnormality of the liver during the course of the study. Aspartate aminotransferase (AST) Alanine aminotransferase (ALT) Upper Limit of Normal (ULN) Results reported in International System of Units (SI)
| Participants | Placebo | Milvexian 25 mg QD | Milvexian 25 mg BID | Milvexian 50 mg BID | Milvexian 100 mg BID | Milvexian 200 mg BID | Milvexian 50 mg QD | Milvexian 100 mg QD |
|---|---|---|---|---|---|---|---|---|
| ALT > 3x ULN | 4 | 2 | 0 | 2 | 3 | 3 | 0 | 0 |
| ALT > 5x ULN | 1 | 0 | 0 | 0 | 2 | 2 | 0 | 0 |
| ALT > 10x ULN | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| ALT > 20x ULN | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| AST > 3x ULN | 6 | 5 | 1 | 4 | 3 | 3 | 1 | 0 |
| AST > 5x ULN | 3 | 2 | 1 | 0 | 2 | 1 | 1 | 0 |
| AST > 10x ULN | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| AST > 20x ULN | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| ALP > 2x ULN | 4 | 5 | 1 | 6 | 4 | 2 | 0 | 0 |
| Total Bilirubin > 1.5x ULN | 10 | 6 | 2 | 7 | 5 | 2 | 0 | 0 |
| Total Bilirubin > 2x ULN | 3 | 1 | 1 | 2 | 2 | 1 | 0 | 0 |
| Concurrent ALT/AST Elevation > 3x ULN with total bilirubin >2x ULN | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
Percent change from baseline in activated partial thromboplastin time (aPTT) activity via exposure response.
| Percent change | Placebo | Milvexian 25 mg QD | Milvexian 25 mg BID | Milvexian 50 mg BID | Milvexian 100 mg BID | Milvexian 200 mg BID | Milvexian 50 mg QD | Milvexian 100 mg QD |
|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in aPTT Activity | 2.47 ± 0.768 | 38.72 ± 2.264 | 58.30 ± 3.195 | 97.32 ± 3.601 | 140.76 ± 5.154 | 193.64 ± 7.041 | 48.48 ± 11.243 | 118.06 ± 13.840 |
Percent change from baseline in factor XI clotting activity via exposure response.
| Percent change | Placebo | Milvexian 25 mg QD | Milvexian 25 mg BID | Milvexian 50 mg BID | Milvexian 100 mg BID | Milvexian 200 mg BID | Milvexian 50 mg QD | Milvexian 100 mg QD |
|---|---|---|---|---|---|---|---|---|
| Percent Change From Baseline in Factor XI Clotting Activity | 4.48 ± 3.455 | -8.88 ± 1.280 | -17.67 ± 1.900 | -37.20 ± 1.655 | -61.52 ± 1.869 | -70.25 ± 3.043 | 3.86 ± 13.754 | -44.27 ± 6.501 |
Pharmacokinetic Parameter - Estimated Clearance (CL). CL is derived from plasma concentration versus time data. PK parameters were generated using a Population Pharmacokinetics (PPK) model. Summary statistics for these individual predicted PK parameters and exposures were stratified by dose. The PPK model analysis was based on combined PK data collected on days 1, 21, and 90.
| L/h | Milvexian 25 mg QD | Milvexian 25 mg BID | Milvexian 50 mg BID | Milvexian 100 mg BID | Milvexian 200 mg BID |
|---|---|---|---|---|---|
| Pharmacokinetic Parameter - Estimated Clearance (CL) | 8.15 ± 34 | 8.01 ± 34.3 | 7.54 ± 32.8 | 7.08 ± 31.3 | 7.43 ± 32.9 |
Pharmacokinetic Parameter - Volume of the Central Compartment (VC). VC is derived from plasma concentration versus time data. PK parameters were generated using a Population Pharmacokinetics (PPK) model. Summary statistics for these individual predicted PK parameters and exposures were stratified by dose. The PPK model analysis was based on combined PK data collected on days 1, 21, and 90.
| L | Milvexian 25 mg QD | Milvexian 25 mg BID | Milvexian 50 mg BID | Milvexian 100 mg BID | Milvexian 200 mg BID |
|---|---|---|---|---|---|
| Pharmacokinetic Parameter - Volume of the Central Compartment (VC) | 34.9 ± 152 | 31.4 ± 138 | 30.9 ± 145 | 28.9 ± 149 | 31.6 ± 181 |
Total volume of diffusion-weighted imaging (DWI) magnetic resonance imaging (MRI) infarcts on the DWI Sequence on day 90 MRI.
| mL | Placebo | Milvexian 25 mg QD | Milvexian 25 mg BID | Milvexian 50 mg BID | Milvexian 100 mg BID | Milvexian 200 mg BID | Milvexian 50 mg QD | Milvexian 100 mg QD |
|---|---|---|---|---|---|---|---|---|
| Volume of Incident Infarcts (New DWI+ or DWI- Lesions) by Participant on Day 90 MRI | 2.3492 ± 11.40906 | 0.8976 ± 1.96342 | 2.9902 ± 8.28993 | 1.2682 ± 2.72452 | 1.4727 ± 3.78795 | 1.2711 ± 4.05035 | 8.8960 ± 13.85294 | 1.4503 ± 1.89112 |
Number of diffusion-weighted imaging (DWI) magnetic resonance imaging (MRI) infarcts on the DWI Sequence on day 90 MRI.
| Participants | Placebo | Milvexian 25 mg QD | Milvexian 25 mg BID | Milvexian 50 mg BID | Milvexian 100 mg BID | Milvexian 200 mg BID | Milvexian 50 mg QD | Milvexian 100 mg QD |
|---|---|---|---|---|---|---|---|---|
| >0 | 82 | 40 | 49 | 36 | 35 | 35 | 3 | 3 |
| 1 | 57 | 26 | 36 | 26 | 24 | 23 | 1 | 2 |
| 2 | 11 | 8 | 5 | 5 | 3 | 6 | 2 | 0 |
| 3 | 8 | 5 | 4 | 1 | 2 | 2 | 0 | 0 |
| 4 | 1 | 1 | 2 | 3 | 2 | 2 | 0 | 1 |
| 5 | 1 | 0 | 0 | 0 | 1 | 2 | 0 | 0 |
| >5 | 4 | 0 | 2 | 1 | 3 | 0 | 0 | 0 |
Secondary analysis of symptomatic ischemic stroke events. Clinical events are included up to day 90. Wald 95% CI within group. Undetermined stroke is included.
| Percentage of participants | Placebo | Milvexian 25 mg QD | Milvexian 25 mg BID | Milvexian 50 mg BID | Milvexian 100 mg BID | Milvexian 200 mg BID | Milvexian 50 mg QD | Milvexian 100 mg QD |
|---|---|---|---|---|---|---|---|---|
| Ischemic stroke | 5.5 (3.8 to 7.2) | 4.6 (2.3 to 6.8) | 3.8 (1.7 to 5.9) | 4.0 (1.9 to 6.1) | 3.5 (1.5 to 5.6) | 7.7 (4.9 to 10.5) | 13.6 (0.0 to 28.0) | 5.6 (0.0 to 16.1) |
| Undetermined stroke | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) |
Collected over Participants were assessed for all-cause mortality from their randomization until their study completion (up to approximately 38 months). SAEs and Other AEs were assessed from first dose to 7 days after last dose of study therapy (up to approximately 112 days).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 5/691 (0.7%) | 94/682 (13.8%) | 178/682 (26.1%) |
| Milvexian 25 mg QD | 4/328 (1.2%) | 37/325 (11.4%) | 81/325 (24.9%) |
| Milvexian 50 mg QD | 0/22 (0%) | 5/22 (22.7%) | 6/22 (27.3%) |
| Milvexian 100 mg QD | 0/18 (0%) | 3/17 (17.6%) | 11/17 (64.7%) |
| Milvexian 25 mg BID | 3/318 (0.9%) | 39/313 (12.5%) | 83/313 (26.5%) |
| Milvexian 50 mg BID | 3/328 (0.9%) | 41/325 (12.6%) | 92/325 (28.3%) |
| Milvexian 100 mg BID | 5/310 (1.6%) | 42/306 (13.7%) | 82/306 (26.8%) |
| Milvexian 200 mg BID | 5/351 (1.4%) | 54/344 (15.7%) | 90/344 (26.2%) |
| Event | Placebo | Milvexian 25 mg QD | Milvexian 50 mg QD | Milvexian 100 mg QD | Milvexian 25 mg BID | Milvexian 50 mg BID | Milvexian 100 mg BID | Milvexian 200 mg BID |
|---|---|---|---|---|---|---|---|---|
| Ischaemic strokeNervous system disorders | 21/682 | 9/325 | 3/22 | 1/17 | 6/313 | 10/325 | 7/306 | 11/344 |
| Basilar migraineNervous system disorders | 0/682 | 0/325 | 0/22 | 1/17 | 0/313 | 0/325 | 0/306 | 0/344 |
| Stroke in evolutionNervous system disorders | 5/682 | 2/325 | 0/22 | 1/17 | 4/313 | 1/325 | 1/306 | 8/344 |
| Acute myocardial infarctionCardiac disorders | 2/682 | 0/325 | 1/22 | 0/17 | 0/313 | 0/325 | 0/306 | 1/344 |
| PneumoniaInfections and infestations | 3/682 | 0/325 | 1/22 | 0/17 | 0/313 | 1/325 | 2/306 | 1/344 |
| Toxic epidermal necrolysisSkin and subcutaneous tissue disorders | 0/682 | 0/325 | 1/22 | 0/17 | 0/313 | 0/325 | 0/306 | 0/344 |
| Urinary tract infectionInfections and infestations | 1/682 | 2/325 | 0/22 | 0/17 | 0/313 | 1/325 | 0/306 | 5/344 |
| Transient ischaemic attackNervous system disorders | 8/682 | 1/325 | 0/22 | 0/17 | 4/313 | 1/325 | 4/306 | 4/344 |
| Acute kidney injuryRenal and urinary disorders | 3/682 | 0/325 | 0/22 | 0/17 | 0/313 | 1/325 | 0/306 | 4/344 |
| Atrial fibrillationCardiac disorders | 4/682 | 3/325 | 0/22 | 0/17 | 1/313 | 0/325 | 3/306 | 0/344 |
| Event | Placebo | Milvexian 25 mg QD | Milvexian 50 mg QD | Milvexian 100 mg QD | Milvexian 25 mg BID | Milvexian 50 mg BID | Milvexian 100 mg BID | Milvexian 200 mg BID |
|---|---|---|---|---|---|---|---|---|
| ConstipationGastrointestinal disorders | 44/682 | 22/325 | 0/22 | 3/17 | 17/313 | 20/325 | 20/306 | 24/344 |
| HeadacheNervous system disorders | 23/682 | 16/325 | 3/22 | 1/17 | 12/313 | 14/325 | 12/306 | 9/344 |
| AnaemiaBlood and lymphatic system disorders | 4/682 | 1/325 | 0/22 | 2/17 | 2/313 | 2/325 | 5/306 | 8/344 |
| NauseaGastrointestinal disorders | 14/682 | 11/325 | 1/22 | 2/17 | 6/313 | 6/325 | 11/306 | 5/344 |
| FatigueGeneral disorders | 6/682 | 2/325 | 0/22 | 2/17 | 3/313 | 1/325 | 2/306 | 4/344 |
| ParaesthesiaNervous system disorders | 3/682 | 0/325 | 1/22 | 2/17 | 0/313 | 0/325 | 1/306 | 1/344 |
| Acute kidney injuryRenal and urinary disorders | 2/682 | 0/325 | 0/22 | 2/17 | 1/313 | 1/325 | 1/306 | 9/344 |
| HypertensionVascular disorders | 56/682 | 21/325 | 0/22 | 2/17 | 23/313 | 24/325 | 20/306 | 19/344 |
| Rectal haemorrhageGastrointestinal disorders | 1/682 | 0/325 | 2/22 | 1/17 | 0/313 | 1/325 | 1/306 | 2/344 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 10/682 | 2/325 | 2/22 | 0/17 | 4/313 | 5/325 | 4/306 | 6/344 |
| Age, Continuous(Years) | Placebo | Milvexian 25 mg QD | Milvexian 25 mg BID | Milvexian 50 mg BID | Milvexian 100 mg BID | Milvexian 200 mg BID | Milvexian 50 mg QD | Milvexian 100 mg QD | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 69.1 ± 10.58 | 70.9 ± 10.66 | 70.1 ± 11.34 | 69.3 ± 10.69 | 69.7 ± 10.59 | 69.5 ± 11.11 | 65.7 ± 10.64 | 65.4 ± 11.65 | 69.6 ± 10.81 |
| Sex: Female, Male(Participants) | Placebo | Milvexian 25 mg QD | Milvexian 25 mg BID | Milvexian 50 mg BID | Milvexian 100 mg BID | Milvexian 200 mg BID | Milvexian 50 mg QD | Milvexian 100 mg QD | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 254 | 109 | 118 | 121 | 112 | 128 | 7 | 10 | 859 |
| Male | 437 | 219 | 200 | 207 | 198 | 223 | 15 | 8 | 1507 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Milvexian 25 mg QD | Milvexian 25 mg BID | Milvexian 50 mg BID | Milvexian 100 mg BID | Milvexian 200 mg BID | Milvexian 50 mg QD | Milvexian 100 mg QD | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 10 | 4 | 2 | 1 | 2 | 1 | 1 | 1 | 22 |
| Not Hispanic or Latino | 62 | 20 | 22 | 23 | 29 | 27 | 7 | 7 | 197 |
| Unknown or Not Reported | 619 | 304 | 294 | 304 | 279 | 323 | 14 | 10 | 2147 |
| Race/Ethnicity, Customized(Participants) | Placebo | Milvexian 25 mg QD | Milvexian 25 mg BID | Milvexian 50 mg BID | Milvexian 100 mg BID | Milvexian 200 mg BID | Milvexian 50 mg QD | Milvexian 100 mg QD | Total |
|---|---|---|---|---|---|---|---|---|---|
| White | 549 | 257 | 246 | 260 | 251 | 288 | 18 | 15 | 1884 |
| Black or African American | 15 | 5 | 6 | 8 | 3 | 5 | 3 | 3 | 48 |
| Asian | 35 | 12 | 21 | 13 | 11 | 17 | 0 | 0 | 109 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 2 |
| Asian Indian | 2 | 1 | 2 | 1 | 0 | 0 | 0 | 0 | 6 |
| Chinese | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Japanese | 84 | 46 | 40 | 41 | 39 | 40 | 0 | 0 | 290 |
| Malay | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Asian Other | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Other | 5 | 6 | 2 | 4 | 5 | 1 | 1 | 0 | 24 |
Showing the first 100 of 424 sites across 29 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2019 to primary completion in Mar 2022, 38 months.
Results were first posted in Jun 2023, 1 year 2 months after primary completion.
Of 41 industry-sponsored phase 2 interventional studies under Ischemic Stroke, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 35. This study's 38 months is above that.
Counting every sponsor, half of 123 studies reached it within 28 months; a quarter within 15 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Milvexian